SCHEMBL24329574

SCHEMBL24329574

CC(C)(C)OC(=O)N1CCC(c2cccc(OCc3ccc(Br)cc3OC3CC3)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.42
PDE4B Q07343 3/20 0.42
PDE4D Q08499 3/20 0.42
PDE4A P27815 2/20 0.42
PDE4C Q08493 2/20 0.42
TRPV3 Q8NET8 1/20 0.40
GLP1R P43220 1/20 0.40
GPR119 Q8TDV5 6/20 0.40
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
KDM1A O60341 1/20 0.39
CACNB4 O00305 1/20 0.39
CACNA1A O00555 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNG3 O60359 1/20 0.39
CACNA1F O60840 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNB3 P54284 1/20 0.39
CACNA2D1 P54289 1/20 0.39
CACNG7 P62955 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30568152 0.90 PDE4D (0.45) PRMT5PDE4BPDE4DPDE4APDE4C
SCHEMBL24329758 0.90 PDE4D (0.45) PRMT5PDE4BPDE4DPDE4APDE4C
SCHEMBL30568144 0.89 GLP1R (0.49) PRMT5TRPV3GLP1RHTT
SCHEMBL24329530 0.89 GLP1R (0.49) PRMT5TRPV3GLP1RHTT
SCHEMBL24329499 0.88 GLP1R (0.45) PRMT5TRPV3GLP1RGPR119TP53
SCHEMBL29555126 0.88 GLP1R (0.41) GLP1R
SCHEMBL24329751 0.87 GLP1R (0.48) TRPV3GLP1R
SCHEMBL24330478 0.82 GLP1R (0.45) PRMT5TRPV3GLP1RGPR119TP53
SCHEMBL25338714 0.82 GLP1R (0.50) GLP1R
SCHEMBL24329504 0.81 GLP1R (0.52) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
CN-116348464-A Benzimidazolone GLP-1 receptor agonists and uses thereof 杭州中美华东制药有限公司 2023-06-27 CN disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR PRMT5 3198/4885PDE4B 587/4885PDE4D 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.